LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, a ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...
Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult ...
Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...
Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company developing next-generation disease-modifying cardiovascular therapeutics, today announced the appointment of three internationally ...
It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...
Background Heart failure with preserved ejection fraction (HFpEF) is characterised by systemic congestion and elevated left ...
Diastolic heart failure means there’s a problem with your heart’s ability to fill with blood. It’s a type of congestive heart failure where your heart cannot work efficiently, leading to fluid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results